COYA vs. DMAC, VTGN, FGEN, ADAG, NVCT, IMUX, ABEO, RZLT, AMLX, and CLRB
Should you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include DiaMedica Therapeutics (DMAC), Vistagen Therapeutics (VTGN), FibroGen (FGEN), Adagene (ADAG), Nuvectis Pharma (NVCT), Immunic (IMUX), Abeona Therapeutics (ABEO), Rezolute (RZLT), Amylyx Pharmaceuticals (AMLX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical preparations" industry.
Coya Therapeutics (NASDAQ:COYA) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.
DiaMedica Therapeutics' return on equity of -36.21% beat Coya Therapeutics' return on equity.
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Coya Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 60.37%. DiaMedica Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 120.82%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Coya Therapeutics.
In the previous week, DiaMedica Therapeutics had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 3 mentions for DiaMedica Therapeutics and 1 mentions for Coya Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.56 beat Coya Therapeutics' score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.
Coya Therapeutics has higher revenue and earnings than DiaMedica Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.
Coya Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.
DiaMedica Therapeutics received 82 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Coya Therapeutics an outperform vote while only 62.07% of users gave DiaMedica Therapeutics an outperform vote.
Summary
DiaMedica Therapeutics beats Coya Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Coya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coya Therapeutics Competitors List
Related Companies and Tools
